UniQure Announces Highlights of Recent Progress

UniQure N.V., a gene therapy company advancing transformative therapies for patients with severe medical needs, reported recent progress across its business.

“Despite the ongoing global crisis caused by the coronavirus pandemic, we ended the first quarter of 2020 in a position of strength and remain well capitalized,” stated Matt Kapusta, chief executive officer of uniQure. “I am very proud of the continued dedication of our employees in both the United States and the Netherlands, and thank them for the outstanding work they continue to do in driving forward our clinical programs, research pipeline, and manufacturing and technology operations.  We are well positioned for an important second half of the year when we expect to announce new clinical data and advancements from across the business.”

Recent Company Progress

Read the press release in its entirety here

Back to all News